812 related articles for article (PubMed ID: 29461447)
21. A comparison of serum IL6 and CRP levels with respect to coronary changes and treatment response in Kawasaki disease patients: a prospective study.
Nandi A; Pal P; Basu S
Rheumatol Int; 2019 Oct; 39(10):1797-1801. PubMed ID: 31302740
[TBL] [Abstract][Full Text] [Related]
22. Coronary artery status of patients with transient fever 24-36 h after first IVIG infusion did not differ from that seen in responsive patients.
Baek JS; Yu JJ; Kim MJ; You J; Jun HO; Kim YH; Ko JK
Pediatr Rheumatol Online J; 2018 Dec; 16(1):83. PubMed ID: 30594188
[TBL] [Abstract][Full Text] [Related]
23. Infliximab as the First Retreatment in Patients with Kawasaki Disease Resistant to Initial Intravenous Immunoglobulin.
Youn Y; Kim J; Hong YM; Sohn S
Pediatr Infect Dis J; 2016 Apr; 35(4):457-9. PubMed ID: 26673981
[TBL] [Abstract][Full Text] [Related]
24. Recent advances in the treatment of Kawasaki disease.
Weng KP; Ou SF; Lin CC; Hsieh KS
J Chin Med Assoc; 2011 Nov; 74(11):481-4. PubMed ID: 22100015
[TBL] [Abstract][Full Text] [Related]
25. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol.
Eleftheriou D; Moraes YC; Purvis C; Pursell M; Morillas MM; Kahn R; Mossberg M; Kucera F; Tulloh R; Standing JF; Swallow V; McCormack R; Herberg J; Levin M; Wan M; Klein N; Connon R; Walker AS; Brogan P
Trials; 2023 Jan; 24(1):60. PubMed ID: 36703139
[TBL] [Abstract][Full Text] [Related]
26. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease.
Bal AK; Prasad D; Umali Pamintuan MA; Mammen-Prasad E; Petrova A
Pediatr Neonatol; 2014 Oct; 55(5):387-92. PubMed ID: 24636168
[TBL] [Abstract][Full Text] [Related]
27. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
Burns JC; Roberts SC; Tremoulet AH; He F; Printz BF; Ashouri N; Jain SS; Michalik DE; Sharma K; Truong DT; Wood JB; Kim KK; Jain S;
Lancet Child Adolesc Health; 2021 Dec; 5(12):852-861. PubMed ID: 34715057
[TBL] [Abstract][Full Text] [Related]
28. Corticosteroid Therapy Might be Associated with the Development of Coronary Aneurysm in Children with Kawasaki Disease.
Zhao CN; Du ZD; Gao LL
Chin Med J (Engl); 2016 Apr; 129(8):922-8. PubMed ID: 27064036
[TBL] [Abstract][Full Text] [Related]
29. Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease.
Kobayashi T; Inoue Y; Otani T; Morikawa A; Kobayashi T; Takeuchi K; Saji T; Sonobe T; Ogawa S; Miura M; Arakawa H
Pediatr Infect Dis J; 2009 Jun; 28(6):498-502. PubMed ID: 19504733
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for coronary arterial involvement in Turkish children with Kawasaki disease: a multicenter retrospective study.
Türkuçar S; Kaya ÜA; Çakmak F; Haşlak F; Demir F; Karabulut E; Makay B; Bilginer Y; Ayaz NA; Sözeri B; Kasapçopur Ö; Karagöz T; Ünal N; Özen S; Ünsal E
Turk J Pediatr; 2023; 65(1):64-72. PubMed ID: 36866986
[TBL] [Abstract][Full Text] [Related]
31. Persistent monocytosis after intravenous immunoglobulin therapy correlated with the development of coronary artery lesions in patients with Kawasaki disease.
Kuo HC; Wang CL; Liang CD; Yu HR; Chen HH; Wang L; Yang KD
J Microbiol Immunol Infect; 2007 Oct; 40(5):395-400. PubMed ID: 17932598
[TBL] [Abstract][Full Text] [Related]
32. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
[TBL] [Abstract][Full Text] [Related]
33. Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population.
Friedman KG; Gauvreau K; Hamaoka-Okamoto A; Tang A; Berry E; Tremoulet AH; Mahavadi VS; Baker A; deFerranti SD; Fulton DR; Burns JC; Newburger JW
J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27633390
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance of serum soluble TNF receptor II level and soluble TNF receptor II/I ratio as indicators of coronary artery lesion development in Kawasaki disease.
Shimizu M; Mizuta M; Usami M; Inoue N; Sakakibara Y; Yamada K; Konishi M; Ohta K; Yachie A
Cytokine; 2018 Aug; 108():168-172. PubMed ID: 29625336
[TBL] [Abstract][Full Text] [Related]
35. Kawasaki disease: a comprehensive review of treatment options.
Patel RM; Shulman ST
J Clin Pharm Ther; 2015 Dec; 40(6):620-5. PubMed ID: 26547265
[TBL] [Abstract][Full Text] [Related]
36. Predictors for Intravenous Immunoglobulin Resistance in Patients with Kawasaki Disease.
Li W; Zhang L; Wang Z; He X; Lin H; Wang Y; Yuan J; Xie X; Zhang X; Qin Y; Huang P
Int J Clin Pract; 2022; 2022():2726686. PubMed ID: 35989868
[TBL] [Abstract][Full Text] [Related]
37. Targeted Use of Prednisolone with Intravenous Immunoglobulin for Kawasaki Disease.
Sakai H; Iwashima S; Sano S; Akiyama N; Nagata E; Harazaki M; Fukuoka T
Clin Drug Investig; 2021 Jan; 41(1):77-88. PubMed ID: 33341911
[TBL] [Abstract][Full Text] [Related]
38. Outcomes in Kawasaki disease patients with coronary artery abnormalities at admission.
Ae R; Abrams JY; Maddox RA; Schonberger LB; Nakamura Y; Kuwabara M; Makino N; Matsubara Y; Matsubara D; Kosami K; Sasahara T; Belay ED
Am Heart J; 2020 Jul; 225():120-128. PubMed ID: 32497905
[TBL] [Abstract][Full Text] [Related]
39. Heart Rate, Responsiveness to Intravenous Immunoglobulin, and Coronary Artery Aneurysms in Kawasaki Disease.
Miyakoshi C; Yamamoto Y; Yamakawa M; Fukuhara S
J Pediatr; 2018 Sep; 200():160-165.e5. PubMed ID: 29793867
[TBL] [Abstract][Full Text] [Related]
40. Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.
Lei WT; Chang LS; Zeng BY; Tu YK; Uehara R; Matsuoka YJ; Su KP; Lee PC; Cavalcante JL; Stubbs B; Lin PY; Wu YC; Hsu CW; Chen TY; Chen YW; Yeh PY; Sun CK; Tseng PT; Kao YH
EBioMedicine; 2022 Apr; 78():103946. PubMed ID: 35306339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
